Angiotensin II: dosing and evidence

Regulatory status

Approved by the FDA. Marketed as GIAPREZA, ANGIOTENSIN II. Earliest approval 2017-12-21. Application NDA209360, ANDA216966.

An approval grades as rung 1 on this site, because 21 CFR 314.126 requires adequate and well-controlled human investigations and one cannot be granted without them. It covers specific indications and doses, though, and does not transfer to other uses of the same molecule.

Dosing on file unverified

Start: 20 ng/kg/min IV; Titrate by up to 15 ng/kg/min q5min; Maintenance: ≤40 ng/kg/min; Doses as low as 1.25 ng/kg/min; Max: 40-80 ng/kg/min; N/A (not administered as therapeutic peptide)

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Literature on file 1

human RCT
FDA approval NDA209360, ANDA216966 graded on: an FDA approval (NDA209360, ANDA216966), which requires adequate and well-controlled human investigations — “NDA209360, ANDA216966”

Identity

Space-filling 3D model of Angiotensin II, carbon grey, nitrogen blue, oxygen red — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

2D chemical structure of Angiotensin II — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

Molecular weight: 1046.2
Molecular formula: C50H71N13O12
CAS number: 4474-91-3
PubChem CID: 172198 (Angiotensin II)
UniProt: P01019 (precursor)
InChI key: CZGUSIXMZVURDU-JZXHSEFVSA-N
SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
InChI: InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1

Also called

Angiotensin II (Memory)

Caveat on these identifiers

Source files disagreed on evidence tier for this peptide.

Notes unverified prose

FDA-approved (Giapreza) 2017; vasopressor in septic shock; FDA-approved (Giapreza); DailyMed; ARBs (angiotensin II receptor blockers) associated with 45% lower dementia risk and memory preservation; no direct Angiotensin II peptide dosing for cognition; ARBs associated with 45% lower dementia risk; no therapeutic peptide dosing

Not on file 1

1 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.

amino-acid sequencenothing we hold supplies it

Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.